8-K: Terns Pharmaceuticals Appoints Amy Burroughs as New CEO and Board Member

Terns Pharmaceuticals has appointed Amy Burroughs as its new Chief Executive Officer and a member of the Board of Directors, effective February 7, 2024.

Summary

• Terns Pharmaceuticals has appointed Amy Burroughs as its new CEO, effective February 7, 2024.
• Ms. Burroughs will also join the company's Board of Directors.
• She brings over 25 years of experience in the biotechnology industry, including previous roles as CEO of Cleave Therapeutics and executive positions at Genentech and other companies.
• Ms. Burroughs's compensation includes an annual base salary of $625,000, a potential annual bonus targeted at 50% of her base salary, and stock options and restricted stock units.
• The stock option grant is for 1,250,000 shares, vesting over four years, and the restricted stock unit award is for 150,000 shares, vesting upon achieving certain stock price targets.
• Jill M. Quigley, previously Interim Senior Advisor and Strategy Officer, has transitioned to an independent director role on the Board.

Sentiment

Score: 8

Explanation: The appointment of an experienced CEO is a positive development for the company. The compensation package is standard and the transition of the previous interim advisor to a board role is also positive. The company is well positioned for future growth.

Positives

• The appointment of Amy Burroughs brings a seasoned executive with over 25 years of experience to lead Terns Pharmaceuticals.
• Ms. Burroughs has a strong track record of advancing therapeutics through the drug development process.
• Her experience includes leadership roles at both small and mid-sized companies, as well as experience in commercial, financial, and partnering strategies.
• The compensation package for Ms. Burroughs includes performance-based incentives, aligning her interests with the company's success.
• The transition of Jill M. Quigley to an independent director ensures continued board expertise.

Risks

• The vesting of restricted stock units is contingent on achieving specific stock price targets, which may not be met.
• The company's future success is dependent on the performance of the new CEO and her ability to execute the company's strategy.
• The company's forward-looking statements are subject to risks and uncertainties, including those related to research and development activities and clinical trials.

Future Outlook

The company expects the new CEO to lead the company in its next stage of growth, advancing programs to later stage development and partnership. The company also has a strong balance sheet, capabilities, and people to execute on both near-term and longer-term value drivers in oncology and metabolic diseases.

Management Comments

• David Fellows, chairman of the board of directors, stated that Amy Burroughs's leadership experience will be incredibly valuable as they advance their programs.
• Amy Burroughs stated that she is privileged to work with the Terns team and continue the progress made over the last five years.

Industry Context

The appointment of a new CEO is a significant event for a clinical-stage biopharmaceutical company like Terns. The company is focused on developing small-molecule product candidates for oncology and obesity, which are areas of high unmet medical need and significant market potential. The new CEO's experience in drug development and commercialization will be crucial for the company's future success.

Comparison to Industry Standards

• The compensation package for the new CEO, including a base salary, bonus potential, and equity awards, is generally in line with industry standards for publicly traded biotechnology companies.
• The vesting schedule for the stock options and restricted stock units is also typical, with vesting over a four-year period and performance-based vesting conditions.
• The appointment of a CEO with experience at companies like Genentech and Cleave Therapeutics is a positive sign for Terns, as these companies are known for their success in drug development and commercialization.
• Tenaya Therapeutics, where Ms. Burroughs serves on the board, is a comparable publicly traded biotechnology company, and her experience there could be beneficial to Terns.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of a new CEO with extensive industry experience as a positive development.
• Employees will be working under new leadership and may experience changes in company strategy and culture.
• Customers and partners may see the new CEO as a sign of stability and growth potential.

Next Steps

• The new CEO will work with the Board to establish performance objectives for 2024.
• The company will continue to advance its clinical-stage development programs.
• The company will continue to execute on its current development strategy.

Key Dates

Keywords

CEO, Chief Executive Officer, Amy Burroughs, Board of Directors, biopharmaceutical, stock options, restricted stock units, executive appointment, Terns Pharmaceuticals, leadership